vs
Essex Property Trust（ESS）与EXACT SCIENCES CORP（EXAS）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Essex Property Trust的1.8倍（$878.4M vs $479.6M），Essex Property Trust净利率更高（17.9% vs -9.8%，领先27.7%），EXACT SCIENCES CORP同比增速更快（23.1% vs 5.5%），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 6.0%）
Essex Property Trust是一家公开上市的房地产投资信托企业，重点布局美国西海岸优质不动产市场，核心投资标的为加利福尼亚州及西雅图大都会区的公寓类物业，在长租公寓的投资、运营及管理领域拥有深厚的行业积累与资源优势。
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
ESS vs EXAS — 直观对比
营收规模更大
EXAS
是对方的1.8倍
$479.6M
营收增速更快
EXAS
高出17.6%
5.5%
净利率更高
ESS
高出27.7%
-9.8%
两年增速更快
EXAS
近两年复合增速
6.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $479.6M | $878.4M |
| 净利润 | $85.7M | $-86.0M |
| 毛利率 | 70.0% | 70.1% |
| 营业利润率 | 31.7% | -9.4% |
| 净利率 | 17.9% | -9.8% |
| 营收同比 | 5.5% | 23.1% |
| 净利润同比 | -71.6% | 90.1% |
| 每股收益（稀释后） | $1.24 | $-0.45 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESSEXAS
| Q4 25 | $479.6M | $878.4M | ||
| Q3 25 | $473.3M | $850.7M | ||
| Q2 25 | $469.8M | $811.1M | ||
| Q1 25 | $464.6M | $706.8M | ||
| Q4 24 | $454.5M | $713.4M | ||
| Q3 24 | $450.7M | $708.7M | ||
| Q2 24 | $442.4M | $699.3M | ||
| Q1 24 | $426.9M | $637.5M |
净利润ESSEXAS
| Q4 25 | $85.7M | $-86.0M | ||
| Q3 25 | $172.7M | $-19.6M | ||
| Q2 25 | $231.5M | $-1.2M | ||
| Q1 25 | $212.8M | $-101.2M | ||
| Q4 24 | $301.7M | $-864.6M | ||
| Q3 24 | $125.5M | $-38.2M | ||
| Q2 24 | $99.0M | $-15.8M | ||
| Q1 24 | $285.1M | $-110.2M |
毛利率ESSEXAS
| Q4 25 | 70.0% | 70.1% | ||
| Q3 25 | 69.2% | 68.6% | ||
| Q2 25 | 70.7% | 69.3% | ||
| Q1 25 | 69.6% | 70.8% | ||
| Q4 24 | 70.0% | 69.0% | ||
| Q3 24 | 69.5% | 69.4% | ||
| Q2 24 | 70.8% | 69.8% | ||
| Q1 24 | 69.7% | 70.0% |
营业利润率ESSEXAS
| Q4 25 | 31.7% | -9.4% | ||
| Q3 25 | 44.5% | -3.0% | ||
| Q2 25 | 59.5% | -0.3% | ||
| Q1 25 | 55.3% | -13.6% | ||
| Q4 24 | 67.0% | -122.8% | ||
| Q3 24 | 28.6% | -5.6% | ||
| Q2 24 | 31.1% | -3.8% | ||
| Q1 24 | 31.0% | -16.7% |
净利率ESSEXAS
| Q4 25 | 17.9% | -9.8% | ||
| Q3 25 | 36.5% | -2.3% | ||
| Q2 25 | 49.3% | -0.1% | ||
| Q1 25 | 45.8% | -14.3% | ||
| Q4 24 | 66.4% | -121.2% | ||
| Q3 24 | 27.8% | -5.4% | ||
| Q2 24 | 22.4% | -2.3% | ||
| Q1 24 | 66.8% | -17.3% |
每股收益（稀释后）ESSEXAS
| Q4 25 | $1.24 | $-0.45 | ||
| Q3 25 | $2.56 | $-0.10 | ||
| Q2 25 | $3.44 | $-0.01 | ||
| Q1 25 | $3.16 | $-0.54 | ||
| Q4 24 | $4.00 | $-4.69 | ||
| Q3 24 | $1.84 | $-0.21 | ||
| Q2 24 | $1.45 | $-0.09 | ||
| Q1 24 | $4.25 | $-0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $76.2M | $964.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.5B | $2.4B |
| 总资产 | $13.2B | $5.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESSEXAS
| Q4 25 | $76.2M | $964.7M | ||
| Q3 25 | $66.0M | $1.0B | ||
| Q2 25 | $58.7M | $858.4M | ||
| Q1 25 | $98.7M | $786.2M | ||
| Q4 24 | $66.8M | $1.0B | ||
| Q3 24 | $71.3M | $1.0B | ||
| Q2 24 | $55.2M | $946.8M | ||
| Q1 24 | $499.0M | $652.1M |
总债务ESSEXAS
| Q4 25 | — | — | ||
| Q3 25 | $6.4B | — | ||
| Q2 25 | $6.4B | — | ||
| Q1 25 | $6.8B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $6.4B | — | ||
| Q2 24 | $6.2B | — | ||
| Q1 24 | $6.6B | — |
股东权益ESSEXAS
| Q4 25 | $5.5B | $2.4B | ||
| Q3 25 | $5.6B | $2.5B | ||
| Q2 25 | $5.6B | $2.5B | ||
| Q1 25 | $5.6B | $2.4B | ||
| Q4 24 | $5.5B | $2.4B | ||
| Q3 24 | $5.4B | $3.2B | ||
| Q2 24 | $5.5B | $3.2B | ||
| Q1 24 | $5.5B | $3.1B |
总资产ESSEXAS
| Q4 25 | $13.2B | $5.9B | ||
| Q3 25 | $13.2B | $5.9B | ||
| Q2 25 | $13.2B | $5.8B | ||
| Q1 25 | $13.2B | $5.7B | ||
| Q4 24 | $12.9B | $5.9B | ||
| Q3 24 | $12.6B | $6.7B | ||
| Q2 24 | $12.5B | $6.7B | ||
| Q1 24 | $12.9B | $6.4B |
负债/权益比ESSEXAS
| Q4 25 | — | — | ||
| Q3 25 | 1.15× | — | ||
| Q2 25 | 1.14× | — | ||
| Q1 25 | 1.22× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.18× | — | ||
| Q2 24 | 1.13× | — | ||
| Q1 24 | 1.19× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.1B | $151.7M |
| 自由现金流经营现金流 - 资本支出 | — | $120.4M |
| 自由现金流率自由现金流/营收 | — | 13.7% |
| 资本支出强度资本支出/营收 | — | 3.6% |
| 现金转化率经营现金流/净利润 | 12.53× | — |
| 过去12个月自由现金流最近4个季度 | — | $356.8M |
8季度趋势，按日历期对齐
经营现金流ESSEXAS
| Q4 25 | $1.1B | $151.7M | ||
| Q3 25 | $342.6M | $219.9M | ||
| Q2 25 | $216.1M | $89.0M | ||
| Q1 25 | $281.5M | $30.8M | ||
| Q4 24 | $1.1B | $47.1M | ||
| Q3 24 | $316.2M | $138.7M | ||
| Q2 24 | $218.9M | $107.1M | ||
| Q1 24 | $314.9M | $-82.3M |
自由现金流ESSEXAS
| Q4 25 | — | $120.4M | ||
| Q3 25 | — | $190.0M | ||
| Q2 25 | — | $46.7M | ||
| Q1 25 | — | $-365.0K | ||
| Q4 24 | — | $10.7M | ||
| Q3 24 | — | $112.6M | ||
| Q2 24 | — | $71.2M | ||
| Q1 24 | — | $-120.0M |
自由现金流率ESSEXAS
| Q4 25 | — | 13.7% | ||
| Q3 25 | — | 22.3% | ||
| Q2 25 | — | 5.8% | ||
| Q1 25 | — | -0.1% | ||
| Q4 24 | — | 1.5% | ||
| Q3 24 | — | 15.9% | ||
| Q2 24 | — | 10.2% | ||
| Q1 24 | — | -18.8% |
资本支出强度ESSEXAS
| Q4 25 | — | 3.6% | ||
| Q3 25 | — | 3.5% | ||
| Q2 25 | — | 5.2% | ||
| Q1 25 | — | 4.4% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 3.7% | ||
| Q2 24 | — | 5.1% | ||
| Q1 24 | — | 5.9% |
现金转化率ESSEXAS
| Q4 25 | 12.53× | — | ||
| Q3 25 | 1.98× | — | ||
| Q2 25 | 0.93× | — | ||
| Q1 25 | 1.32× | — | ||
| Q4 24 | 3.54× | — | ||
| Q3 24 | 2.52× | — | ||
| Q2 24 | 2.21× | — | ||
| Q1 24 | 1.10× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESS
暂无分部数据
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
